Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary (2011)
Chapter: Acronyms
AACI | Association of American Cancer Institutes |
ACOSOG | American College of Surgeons Oncology Group |
ACRIN | American College of Radiology Imaging Network |
ALL | acute lymphoblastic leukemia |
AMA | American Medical Association |
AML | acute myeloid leukemia |
ASCO | American Society of Clinical Oncology |
ASO | administrative services only |
BIQSFP | Biomarker, Imaging, and Quality of Life Studies Funding Program |
BUN | blood urea nitrogen concentration |
caBIG | Cancer Biomedical Informatics Grid |
CALGB | Cancer and Leukemia Group B |
CAM | complementary and alternative medicine |
CBER | Center for Biologics Evaluation and Research |
CCOP | Community Clinical Oncology Program |
CCSG | Cancer Center Support Grant |
CDER | Center for Drug Evaluation and Research |
CDRH | Center for Devices and Radiological Health |
CEBP | CCAAT/Enhancer Binding Protein |
CED | coverage with evidence development |
CIRB | Central Institutional Review Board |
CLIA | Clinical Laboratory Improvement Amendments |
CME | continuing medical education |
CMS | Centers for Medicare and Medicaid Services |
COG | Children’s Oncology Group |
CPC | Cancer Prevention and Control |
CPT | Common Procedural Terminology |
CRADA | Cooperative Research and Development Agreement |
CRF | case report form |
CT | computed tomography |
CTAC | Clinical and Translational Research Advisory Committee |
CTEP | Cancer Therapy Evaluation Program |
CTSU | Cancer Trials Support Unit |
CTWG | Clinical Trials Working Group |
DCTD | Division of Cancer Treatment and Diagnosis |
ECOG | Eastern Cooperative Oncology Group |
EMA | European Medicines Agency |
ERISA | Employee Retirement Income Security Act |
FDA | Food and Drug Administration |
FLT3/ITD | fms-like tyrosine kinase receptor-3/internal tandem duplication |
FOA | Funding Opportunity Announcement |
GOG | Gynecological Oncology Group |
HCPCS | Healthcare Common Procedure Coding System |
HER2 | human epidermal growth factor receptor 2 |
HHS | U.S. Department of Health and Human Services |
IDE | investigational device exemption |
IND | investigational new drug |
IOM | Institute of Medicine |
IP | intellectual property |
IRB | Institutional Review Board |
IT | information technology |
KRAS | Kirsten ras oncogene |
MTA | Material Transfer Agreement |
NCCN | National Cooperative Cancer Network |
NCCTG | North Central Cancer Treatment Group |
NCI | National Cancer Institute |
NDA | new drug applications |
NHBLI | National Heart, Lung, and Blood Institute |
NIH | National Institutes of Health |
NLM | National Library of Medicine |
NSABP | National Surgical Adjuvant Breast and Bowel Project |
OEWG | Operational Efficiency Working Group |
OHRP | Office for Human Research Protections |
OPEN | Oncology Patient Enrollment Network |
OSU | Ohio State University |
PET-CT | positron emission tomography-computed tomography |
PhRMA | Pharmaceutical Research and Manufacturers of America |
PI | principal investigator |
RECIST | Response Evaluation Criteria in Solid Tumors |
RFA | Request for Applications |
RTOG | Radiation Therapy Oncology Group |
RUC | Relative Value Scale Update Committee |
SACHRP | Secretary’s Advisory Committee on Human Research Protections |
SJO | St. Joseph Hospital, Orange, California |
sNDA | supplemental new drug application |
SPA | Special Protocol Assessment |
SPORE | Specialized Program of Research Excellence |
START | Standard Terms of Agreement for Research Trials |
SWOG | Southwest Oncology Group |
TAILORx | Trial Assigning IndividuaLized Options for Treatment |
TARGET | Therapeutically Applicable Research to Generate Effective Treatments |
